GlassScriptPhysician profile
Donna Cannon
NPI 1306236617
$4,008.35
in general payments reported to CMS, 2019-2025
23 companies · $675 in 2025
The $675 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $725 · 2022: $580 · 2023: $1,034 · 2024: $994 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,641.41 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $924.27 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $530.74 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.59 | 2021-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $389.20 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $368.67 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $249.75 | 2022-2024 | |
| Glaxosmithkline, LLC. | $196.38 | 2021-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $146.35 | 2021-2025 | Jardiance, Mounjaro, Trulicity |
| Amarin Pharma, INC. | $130.38 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.39 | 2025 | Caplyta |
| Amgen INC. | $107.66 | 2023-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $82.59 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $72.18 | 2024 | Austedo Xr |
| Pfizer INC. | $60.69 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $47.93 | 2023-2024 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $47.36 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.46 | 2022-2025 | Trintellix |
| Intuitive Surgical, INC. | $19.84 | 2022 | |
| Abbott Laboratories | $19.75 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $16.02 | 2022 | |
| Mylan Specialty L.P. | $15.63 | 2022 | |
| Esperion Therapeutics, INC. | $12.81 | 2021 | |
| Merck Sharp & Dohme LLC | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.